The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ADMA BIOLOGICS INC. | COM | 000899104 | 16,598 | 3,608,171 | SH | SOLE | 3,608,171 | 0 | 0 | ||
| AGILE THERAPEUTICS INC. | COM | 00847L100 | 3,354 | 1,304,933 | SH | SOLE | 1,304,933 | 0 | 0 | ||
| AIMMUNE THERAPEUTICS INC. | COM | 00900T107 | 71,299 | 2,240,000 | SH | SOLE | 2,240,000 | 0 | 0 | ||
| CHIMERIX INC. | COM | 16934W106 | 2,459 | 472,943 | SH | SOLE | 472,943 | 0 | 0 | ||
| CIDARA THERAPEUTICS INC. | COM | 171757107 | 4,085 | 1,021,148 | SH | SOLE | 1,021,148 | 0 | 0 | ||
| LOXO ONCOLOGY INC. | COM | 548862101 | 396,748 | 3,438,920 | SH | SOLE | 3,438,920 | 0 | 0 | ||
| PERNIX THERAPEUTICS HLDGS INC. | COM NEW | 71426V306 | 502 | 210,000 | SH | SOLE | 210,000 | 0 | 0 | ||
| PERNIX THERAPEUTICS HLDGS INC. | DEBT 4.250% 4/0 | 71426VAK4 | 1,155 | 2,500,000 | PRN | SOLE | 2,500,000 | 0 | 0 | ||
| TRANSENTERIX INC. | COM NEW | 89366M201 | 16,812 | 9,889,352 | SH | SOLE | 9,889,352 | 0 | 0 | ||
| VIEWRAY INC. | COM | 92672L107 | 48,102 | 7,480,887 | SH | SOLE | 7,480,887 | 0 | 0 | ||